Lexaria Bioscience Extends Material Transfer Agreement with PharmaCO Through 2026
Lexaria Bioscience has extended its Material Transfer Agreement with an undisclosed pharmaceutical company to evaluate its DehydraTECH technology for GLP-1 drugs, allowing for continued collaboration and review of upcoming R&D results.
Lexaria Bioscience Corp. (NASDAQ: LEXX), a company specializing in oral drug delivery platforms, announced the extension of its Material Transfer Agreement (MTA) with an unnamed pharmaceutical company (PharmaCO) through December 31, 2026. The original agreement, entered into on August 30, 2024, was designed to evaluate Lexaria’s DehydraTECH™ technology in a pre-clinical setting.
The extension accommodates the time needed for PharmaCO to receive and review Lexaria’s 2026 research and development (R&D) results related to GLP-1 drugs. This allows the two parties to continue their relationship under the MTA, keep the temporary exclusive license active, and engage in additional strategic planning discussions with PharmaCO’s human clinical and business development teams.
The announcement underscores the potential significance of Lexaria’s technology in improving the oral delivery of GLP-1 drugs, a class of medications used for conditions like type 2 diabetes and obesity. Over the past 12 months, Lexaria has advanced its GLP-1 development program, including recently announced progress in three 2026 R&D studies: Human Study #7, Animal Study #1, and Animal Study #2. All studies are designed to provide evidence to facilitate additional collaboration and potential licensing of Lexaria’s technology.
Each of these studies is fully funded with existing corporate resources, and results are expected during Q3 and Q4 of this calendar year. The extension of the MTA suggests that PharmaCO sees promise in Lexaria’s DehydraTECH platform, which aims to enhance the oral delivery of drugs that traditionally require injection, potentially improving patient compliance and outcomes.
DehydraTECH is Lexaria’s patented drug delivery formulation and processing platform technology. It has repeatedly shown the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. More information can be found at www.lexariabioscience.com.
The extension is a positive signal for Lexaria, as it maintains a potential path to commercialization through a partnership with a pharmaceutical company. However, as with all forward-looking statements, there are risks and uncertainties, including those related to the completion and results of the studies, regulatory approvals, and the ability to realize the benefits of collaborations. The original press release can be accessed on NewMediaWire.